No Data
No Data
As of July 10th, Chongqing Lummy Pharmaceutical (300006.SZ) had a shareholder count of 31,391.
On July 15th, Gelunhui reported that as of July 10th, 2024, the number of shareholders in Chongqing Lummy Pharmaceutical (300006.SZ) was 31,391 on the investor interaction platform.
Chongqing Lummy Pharmaceutical (300006.SZ): The Replicor hepatitis B drug development project is currently steadily progressing.
Chongqing Lummy Pharmaceutical (300006.SZ) stated on the investor interaction platform on June 12 that the company holds 0.75% equity of Replicor Company through its wholly-owned subsidiary Lai Mei Hong Kong. Replicor Company's hepatitis B drug development project is currently making steady progress, and the company will closely monitor the progress of the project and fulfill its information disclosure obligations in a timely manner in accordance with the relevant regulations of the Shenzhen Stock Exchange.
Retail Investors Are Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) Biggest Owners and Were Hit After Market Cap Dropped CN¥412m
Chongqing Lummy Pharmaceutical (300006.SZ): Qiu Yu and Guangxi Wuzhou Zhongheng Group have signed a "Voting Rights Proxy Agreement".
<表决权委托协议>Gelonghui, June 5, 丨 Laimei Pharmaceutical (300006.SZ) announced that shareholder Mr. Qiu Yu signed a “Supplementary Agreement” with the controlling shareholder Guangxi Wuzhou Zhongheng Group Co., Ltd. (“Zhongheng Group”) on April 7, 2023. The agreement will expire on June 7, 2024. On June 4, 2024, Mr. Qiu Yu and Zhongheng Group signed the “Voting Rights Entrustment Agreement”. The voting rights entrustment period is until June 7, 2026. The signing of this agreement will not lead to a change in the control of listed companies, nor will it trigger the “Administrative Measures on Acquisitions of Listed Companies”
Lummy Pharmaceutical Gets Nod to Market Naloxone Hydrochloride Injection
Guangxi Wuzhou Zhongheng Group (600252.SH): Its holding subsidiary Naloxone hydrochloride injection has obtained the pharmaceutical registration certificate.
On June 4th, Gelonhui reported that Guangxi Wuzhou Zhongheng Group (600252.SH) announced that its holding subsidiary, Chongqing Lummy Pharmaceutical Co., Ltd. ('Lummy Pharmaceutical'), received the 'Drug Registration Certificate' issued by the National Medical Products Administration for the specification of 1ml:0.4mg naloxone hydrochloride injection. The naloxone hydrochloride injection is developed by ADAPT Pharmaceuticals in the United States, is currently available in the United States and Japan, and has not yet been imported into China. Naloxone hydrochloride injection is an opiate receptor antagonist used to counteract the respiratory depression caused by opiate drugs during compound anesthesia, and to promote patient awakening; it is also used for opiate
No Data